



BIONXT MARKETING SERVICES

VANCOUVER, BC – June 28, 2024 - BioNxt Solutions Inc. (“**BioNxt**” or the “**Company**”) (CSE: BNXT / OTCQB: BNXTF / FSE: BXT), a specialized European drug developer, is pleased to report that it has engaged three marketing groups to provide Promotional Activity pursuant to Policy 7 of the Canadian Securities Exchange.

Martin City Studios LLC, Albuquerque, USA, to conduct two voice interviews to air on VoiceAmerica.com/Business Channel and Money TalkRadio with Ellis Martin. The interviews will be conducted and aired in July and/or August 2024 and downloadable on iTunes, TuneIn, Stitcher Radio, Spotify, and YouTube, and distributed by ABN Newswire reaching Bloomberg, Thomson Reuters and over 3.1 Million subscription based financial terminals and market information systems in the Americas, Asia and Europe. Martin City Studios LLC will be paid \$6,500 USD. No equity compensation will be paid.

Equity.Guru Media Inc., Vancouver, Canada, to provide monthly content creation, including digital print articles and video content to be featured on Equity.Guru, ParryResearch, and HoweStreetReporter.com, newsletters to their opt-in investor community, and updates on their social media platforms, including LinkedIn and Twitter. The activities are designed to enhance brand visibility, educate and engage stakeholders, and drive investor engagement and will be provided up to December 31, 2024. Equity.Guru Media Inc. will be paid \$10,000 CAD plus applicable taxes. No equity compensation will be paid.

Cayo Ventures GmbH, Zug, Switzerland, to provide German language video interviews, opt-in email news distribution, and digital marketing services. The services are designed to engage younger European investors with strategic communication using online platforms. Services will be provided in Europe for July and August 2024 with compensation up to Euro 20,000 per week depending on success as measured via observed trading activity in Europe. No equity compensation will be paid.

The Company also announces that, with its almost exclusive focus on German-based drug development and commercialization, Hugh Rogers, CEO and director of BioNxt, based in Vancouver, Canada, will step down from his role as CEO effective July 1, 2024. Wolfgang Probst, director of BioNxt, will act as interim CEO as the Company continues to expand its focus on German operations and drug development collaborations.

About BioNxt Solutions Inc.

BioNxt Solutions Inc. is a bioscience accelerator focused on next-generation drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical production and evaluation, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications. The Company has research and development operations in North America and Europe, with an operational focus in



Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.

BioNxt Solutions Inc.

Hugh Rogers, CEO and Director

Email: info@bionxt.com

Phone: +1 780-818-6422

Cautionary Statement Regarding “Forward-Looking” Information

Some of the statements contained in this news release are forward-looking statements and information within the meaning of applicable securities laws. Forward-looking statements and information can be identified by the use of words such as “expects”, “intends”, “is expected”, “potential”, “suggests” or variations of such words or phrases, or statements that certain actions, events or results “may”, “could”, “should”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements and information are not historical facts and are subject to a number of risks and uncertainties beyond the Company’s control. Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this news release. Accordingly, readers should not place undue reliance on forward-looking statements. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements, except as may be required by law.